What is good quality data?

Slides:

Advertisements

Similar presentations

4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.

Advertisements

Rare Blood Disorder Initiative, Blood Surveillance Sept 30, 2006 Bruce Ritchie Hematology, University of Alberta, Edmonton, Alberta.

St. John Ambulance Council for Ontario Mission Statement.

Real-World Prophylaxis Experience: Perspectives from Clinical Practice Alfonso Iorio MD, PhD McMaster University Canada BeneF IX ® (nonacog alfa) is not.

The situation The requirements The benefits What’s needed to make it work How to move forward.

15th Annual Primary Care Update May 8-12, 2012

How Two Bioethics Networks Can Network Carolyn Ells, PhD Co-coordinator, FAB Associate Professor, Medicine, McGill University.

Internal Control. COSO’s Framework Committee of Sponsoring Organizations 1992 issued a white paper on internal control Since this time, this framework.

Assessment of long term safety and efficacy of clotting factor concentrates Alfonso Iorio, MD, PhD Health Information Research Unit & Hemophilia Program.

Annual Certifications 1. Completing an Annual Certification Form The purpose of the Annual Certification is to ensure that faculty have reported all of.

2012 National PBIS Leadership Forum Hyatt Regency O’Hare Rosemont Illinois October 18-19th 2012 School-wide PBIS: A Framework for Effective Teaching &

North Shore – LIJ Health System PREP Workshop #4: How to Report and Manage External Interests (COIs) Electronically.

Adrienne S. Chan, PhD University of the Fraser Valley Canada.

An Indirect Comparison of the Efficacy of Prophylactic Use of rFIXFc and rFIX Products and Simulation of the Effect of Compliance on Effectiveness Alfonso.

ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience Alfonso Iorio, MD, PhD.

UAMS College of Medicine New Faculty Orientation August 24 th, 2010 Opening SessionClinician SessionResearch Session.

CHECK IT OFF! Did you complete your paperwork?. 10/25/2015 Sign in Sheet 1.Please make sure you have signed the sign in sheet. 2.If it is an all day session,

Hosted by: Institute for Software Integrated Systems (ISIS) Vanderbilt University Software Reliability for FCS May 18-19, 2004 ARO Workshop.

Inhibitor development according to FVIII concentrate in PUPs: how to interpret current evidence? Alfonso Iorio Health Information Research Unit & Hamilton-Niagara.

Inhibitor reporting standardization in previously treated patients Alfonso Iorio ISTH SSC – Factor VIII/IX Saturday June 20, 2015 Room 10:20 Room: 718.

Advances in Technology: How can we Assess the Potential, and then Confirm the Reality Alfonso Iorio, MD, PhD Health Information Research Unit & Hemophilia.

Non-adherence and its impact on treatment efficacy

WAPPS project (web accessible pharmacokinetics service)

H OW TO MEASURE PROGRESS IN THE PROVISION OF CARE FOR HEMOPHILIA Alfonso Iorio J Stonebraker, M Brooker, M Soucie. A workgroup of the Data and Demographics.

Strategies for Permanent Access to Scientific Information in Southern Africa: Health and Environmental Information for Sustainable Development Pretoria,

With Co-Chairs: Dr Chris Barnes and Dr Simon McRae

EVIDENCE BASED HAEMOPHILIA CARE – CURRENT STATUS AND WHERE TO GO? Alfonso Iorio Health Information Research Unit & Hamilton-Niagara Hemophilia Program.

Title of the presentation

Working group on Pharmacokinetics and Population Pharmacokinetics of factor concentrates Alfonso Iorio, on behalf of the working group.

Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &

This meeting is intended for non-US journalists only

Professor Roger Strasser AM, Dean Northern Ontario School of Medicine

“Understanding Prostate Cancer”

eCOI electronic Conflict of Interest

Chapter 5 ASX Guidelines for Listed Companies

CURRENT ADVERSE EVENTS REPORTING IN HEMOPHILIA

Managing Inhibitor Risk in both PUPs and PTPs

FACULTY/PRESENTER DISCLOSURE

Oncology Grand Rounds “Targetting the Undruggable: Past Attempts

Conflict of Interest Disclosure

Conflict of Interest Disclosure

Working Group on Pharmacokinetics and Population Pharmacokinetics

Oncology Grand Rounds “Potentially Lethal Prostate Cancer:

Composition of the National Advisory Panel

Alfonso Iorio, on behalf of the working group

Title of the presentation

Conflict of Interest Disclosure Form

ACS Users Group Gregg Bell, PhD SDC Steering Committee Alexandria, VA

Disclosures for Elizabeth Bengtson, MD

Conflict of Interest Disclosure (over the past 24 months)

FINANCIAL DISCLOSURES

Safety and Accident Prevention

Welcome to the 39th ESPEN Congress

Conflict of Interest Disclosure

Student, Parent & Community Engagement

Talk Title 40pt Bold Calibri

Please Join our Workshop on

THE AGDI PROCESS METHODOLOGY WORKSHOP FOR PHASE 4 OF THE AFRICAN GENDER AND DEVELOPMENT INDEX 7-8 JUNE 2016 ADDIS ABABA, ETHIOPIA.

Conflict of Interest Disclosure

Talk Title 40pt Bold Calibri

Conflict of Interest Disclosure Form

Albuquerque Public Schools

Title of the presentation

Talk Title 40pt Bold Calibri

Financial Disclosure Financial Interest / Affiliation

Conflict of Interest Disclosure Form DISCLOSURE

Joyce Backus Associate Director, Library Operations

Name of Activity / Session

Conflict of Interest Disclosure Form

KUMC Faculty Research Day

Presentation transcript:

What is good quality data? Alfonso Iorio MD, PhD Health Information Research Unit McMaster University, Canada What is good quality data? - Alfonso Iorio, Canada

Disclosures for: Alfonso Iorio In compliance with the PIM* policy, WFH requires the following disclosures be made at each presentation CONFLICT Disclosure — if conflict of interest exists Research Support McMaster receives support for research in hemophilia by Bayer, Biogen, Octapharma, Novo-Nordisk, Pfizer, Shire Director, Officer, Employee Data and Demographics committee, WFH Shareholder Honoraria Advisory Committee McMaster receives support for services in hemophilia by Bayer, Biogen, Octapharma, Novo-Nordisk, Pfizer, Shire Consultant * Postgraduate Institute for Medicine 2

Quality Data Trustworhty Appropriate Understandable Powerful Trustworthy Appropriate Understandable Powerful

Trustworthiness Precise Accurate Reproducible Face validity 4

5

Time Participants 8:30 110 8:45 160 10:20 90 11:00 75 Trustworthiness

Time Participants 8:30 110 8:45 160 10:20 90 11:00 75 Trustworthiness

Time Participants Max Min Mean 108 Trustworthiness Time Participants 8:30 110 8:45 160 Max 10:20 90 11:00 75 Min Mean 108 8

How many participants? How many seats? How many lunch-boxes? APPROPRIATENESS How many participants? Time Participants 8:30 110 8:45 160 Max 10:20 90 11:00 75 Min Mean 108 How many seats? How many lunch-boxes? 9

How many language translations? APPROPRIATENESS Name Country E-mail Arthur Santos Brazil as@gmail.com Andrea Muller UK millera@nhs.nhr.uk Andreas Solo US js98@providence.edu Andrea White Argentina a.white@live.com Erinn McGill Canada mcgille@live.com …... How many women? How many language translations? 10

Fatal/total accidents Understandable This year, the number of fatal street accident increased by 15 Cirxulating cars Car accidents Fatal/total accidents +10% -2% +10.000/100,000 +200/2000 +15 (525) +25,000/2M -1,000/15,000 +15 (830) +1,000/15,000 +15 (1700) 11

Time Workshop A Workshop B Workshop C Mean 108 62 115 POWERFUL Time Workshop A Workshop B Workshop C 8:30 110 50 140 8:45 160 80 120 10:20 90 70 11:00 75 60 Mean 108 62 115 12

Time Workshop A Workshop B Workshop C 160 Mean 108 62 115 POWERFUL Time Workshop A Workshop B Workshop C 8:30 110 50 140 8:45 160 80 120 10:20 90 70 11:00 75 60 Mean 108 62 115 13

Time Workshop A Workshop B Workshop C 50 Mean 108 62 115 POWERFUL Time Workshop A Workshop B Workshop C 8:30 110 50 140 8:45 160 80 120 10:20 90 70 11:00 75 60 Mean 108 62 115 14

Time Workshop A Workshop B Workshop C Mean 108 62 115 POWERFUL Time Workshop A Workshop B Workshop C 8:30 110 50 140 8:45 160 80 120 10:20 90 70 11:00 75 60 Mean 108 62 115 15

Time Workshop A Workshop C Mean 108 115 POWERFUL Details: Room A: 75 seats Room C: 200 seats, free breakfast Time Workshop A Workshop C 8:30 110 140 8:45 160 120 10:20 90 11:00 75 60 Mean 108 115 Critical detail: Plenary session (with free lunch) at 10:30 16

Ask important questions Collect reliable and appropriate data SUMMARY Ask important questions Collect reliable and appropriate data Empower your data with proper comparators and meaningful covariates 17